RedOak Instruments

RedOak Instruments

Early Stage

Red Oak Instruments produces biomedical devices that allow quantitative measurements of fine motor skills.

Red Oak Instruments produces biomedical devices that allow quantitative measurements of fine motor skills.


Raised to Date: Raised: $47,780

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Katy, Texas

Business Type


RedOak Instruments, with a post-money valuation of $7.9 million, is raising a RegCF round on NetCapital. The company makes biomedical devices that help in the quantitative measurement of fine motor skills. The instruments allow doctors to measure patients’ functionality, helping them with their diagnosis. Richard Behlmann founded RedOak Instruments in 2008. The proceeds of the current crowdfunding round, with a minimum goal of $10,000 and a maximum goal of $1,000,000, will be used for software development, marketing and sales, development of tech support, manufacturing, compensation, and staff support. The medical device of RedOak Instruments is FDA approved, quick, and non-invasive. The company will either sell or lease the instrument to generate initial revenue of about $5,000 per device per year.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 02/20/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
RedOak Instruments 04/22/2021 Netcapital $6,927,896 $47,780 Equity - Common Funded RegCF
RedOak Instruments 02/27/2021 Netcapital $7,927,896 $0 Equity - Common Funded Test the Waters
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


Injuries occur indiscriminately to people from all walks of life, but they are infamously frequent among athletes. Every year, more than 3.5 million sports injuries occur among children and teenagers alone. A clear demand exists for giving athletes prompt medical treatment. However, many of these injuries go unreported, leading to potential complications. RedOak Instruments is a company that operates within the sports and medical technology industries. The company’s product (the RU-Fit Device) is designed to monitor fine motor skills in athletes, simultaneously creating opportunities for them to improve in sports and diagnosing concussions or other injuries before they become severe.

The sports medicine industry is a rapidly growing one (currently estimated to be worth $8.1 billion), especially with head injuries being as frequent for young athletes as they are. There are an estimated 300k sports-related traumatic head injuries for people ages 15-24 in the United States, making sports injuries the second-leading cause of traumatic brain injury for this age range.

RedOak Instruments’ Fine Motor Control screening method has been FDA approved, and the company claims in its current raise that the equipment is ready to be sold. However, the company has been around since 2008 and has seemingly very little to show for it product-wise or financially. The potential is there, and the company’s product can definitely be applied to many different sports, but there doesn’t seem to be much in terms of preexisting traction.

RedOak Instruments’ current Netcapital raise has been rated a Neutral Deal from the KingsCrowd investment team.

Next Section: Price


RedOak Instruments is currently raising at a $6,927,896 valuation. At first glance, this amount seems low in comparison to many other startups currently available for investment. However, RedOak received no revenue in the most recent fiscal year and went from $126,565 cash on-hand last year to $17,987 cash on-hand this year. The lack of revenue makes the company’s $6.9 million valuation entirely unjustified. Thus, the price score for RedOak Instruments is low.

Next Section: Market


Globally, the sports medicine market was valued at $8.1 billion in 2019. There has been a recent uptick in participation in sports and exercise amongst Americans. Nearly 20% of all people under the age of 15 partook in some form of exercise in 2015, compared to 15.9% in 2003. This rise in playing sports has in turn led to a rise in sports injuries, growing the possible market that RedOak will have access to.

The global traumatic brain injury assessment and management devices market was valued at $2.9 billion in 2020. RedOak plans on having wider medical applications on top of its sports applications. Its proposed product can be easily utilized in various physically demanding industries in which knowledge of an injury ahead of time would be beneficial. The ability to expand into other markets is possible for the company, but it has little existing market success to indicate expansion is close.  

Due to the small size of RedOak’s current target markets, the company scores poorly in the market metric.

Next Section: Team


ROI’s current CTO, William C. Paske, is a co-founder of the company as well as the mind behind its fine motor control measurement technology. Paske has an MS degree in Nuclear Physics and a PhD in Atomic and Molecular Physics. He has 10 US patents to his name, including the technology used by RedOak. He is joined at the company by president and CEO Richard Behlmann. Behlmann has his JD from St. Mary’s University of Law and oversees the business strategy and sales. Behlmann’s dedication to the company is questionable as he is also an actively practicing lawyer and managing his own firm.

The team is rounded out by David and Charles Paske (COO and vice president of market development, respectively), Vice President of IT David Hinote, and Software Development Lead Daniel Stewart. The team does have a wide variety of experience with degrees in fields like mechanical engineering, physics, electrical engineering, computer science, and law. This diversity of skill sets is an asset at any startup and hopefully allows for RedOak to keep inventing cutting-edge technology. Therefore, RedOak Instruments team score is its highest across all five metrics.

Next Section: Differentiators


Most diagnoses need to be given by a licensed professional and are subjective. RedOak Instruments’ tests can be given by anyone with one hour of training and provide metrics that are easily compared over time. This functionality is meant to create an objective picture of the progress made by a patient and the signs of injury. The duration of its test — under 10 minutes — is also a huge differentiator for RedOak. Additionally, the company has secured patents for its technology, lending defensibility.

The company identifies Positron Emission Tomography as a competing technology that also allows for repeated and reproducible tests. However, the price point and time needed for these tests is much higher than RedOak’s.

Due to these many distinctions from current technology, RedOak Instruments has a strong differentiators score.

Next Section: Performance


RedOak Instrument’s performance thus far, 13 years into existence, is negligible. The medical instrument created by William Paske does have FDA approval, and the company says it has 100 testing systems already constructed and ready to be sold. As of now, however, there has been no actual progress in doing so.

RedOak’s technology has been beta tested and used by orthopedic surgeons, psychologists, and epidemiologists,indicating potential for widespread approval and traction. Financially, RedOak has very little to show. Cash on hand dropped from around $126,000 in the previous fiscal year to just under $18,000 in the most recent fiscal year. That type of cash burn for a company that also has no revenue is not a good indicator for future success. As a result, the performance score for RedOak Instruments is middling.

Next Section: Bearish Outlook

Bearish Outlook

RedOak Instruments has been in existence for 13 years but has very little to show for it. With barely any product and lack of existing partnerships to inspire hope in future success, RedOak seems like it is on the wrong path. The CEO isn’t firmly committed to the company and could fall behind the competition or lose interest altogether. Overall, RedOak Instruments has had a shaky past and seems to have an even shakier future.

Next Section: Bullish Outlook

Bullish Outlook

RedOak Instruments’ technology has already been patented and FDA approved, allowing it to sell its product freely. The company alleges to have 100 instruments ready to be sold. If its initial beta testing yields interested parties, revenue could start coming in. With more people participating in exercise and sports, there are increased opportunities for RedOak to sell its instruments. Additionally, it’s possible that the company’s solution could have applications outside of sports. If it expands its market aspirations to include various other industries where regular physical check-ups are important, it will have many more sales opportunities.

Next Section: Executive Summary

Executive Summary

RedOak Instruments is a company that has been around since 2008 and still operates with no revenue. The CEO runs a law firm alongside his work with RedOak, calling into question his dedication to the company. With little product to speak of, no existing partnerships, and no immediate opportunities presented, the company’s future seems shaky. However, the industry is growing, and the product has wide applications in the field of medicine, especially in relation to sports. A solid review from an early adopter of RedOak Instruments’ product could put them on the right path. Factoring everything in, RedOak Instruments has been rated a Neutral Deal.

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to

Analysis written by Ethan Thomas.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
RedOak Instruments on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $6,927,896
Price per Share: $2.00

Follow company

Follow RedOak Instruments on Netcapital

Buy RedOak Instruments's Deal Report

Warning: according to the close date for this deal, RedOak Instruments may no longer be accepting investments.

RedOak Instruments Deal Report

Get KingsCrowd’s comprehensive report on RedOak Instruments including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether RedOak Instruments is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the RedOak Instruments deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge